HMGB1-Driven Inflammation and Intimal Hyperplasia after Arterial Injury Involves Cell-Specific Actions Mediated by TLR4

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 35, Issue 12, 2015, Pages 2579-2593

  Cai, Jingjing ^a,c,d   Yuan, Hong ^a,c   Wang, Qingde ^a,d   Yang, Huan ^e   Al Abed, Yousef ^e   Hua, Zhong ^a,d   Wang, Jiemei ^d   Chen, Dandan ^d   Wu, Jinze ^a,d   Lu, Ben ^b   Pribis, John P ^d   Jiang, Weihong ^c   Yang, Kan ^c   Hackam, David J ^d   Tracey, Kevin J ^e   Billiar, Timothy R ^d   Chen, Alex F ^b,d  

^a THE THIRD XIANGYA HOSPITAL OF CENTRAL SOUTH UNIVERSITY   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

^c CENTRAL SOUTH UNIVERSITY   (China)

^d UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^e FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

Author keywords

Angioplasty; carotid artery injuries; HMGBI protein; hyperplasia; macrophages

Indexed keywords

ADVANCED GLYCATION END PRODUCT; BONE MORPHOGENETIC PROTEIN 9; DISULFIDE; HIGH MOBILITY GROUP B1 PROTEIN; MONOCYTE CHEMOTACTIC PROTEIN 1; MONOCYTE CHEMOTACTIC PROTEIN 2; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; AUTACOID; CYTOKINE; HMGB1 PROTEIN, HUMAN; HMGB1 PROTEIN, MOUSE; MYD88 PROTEIN, MOUSE; MYELOID DIFFERENTIATION FACTOR 88; TICAM-1 PROTEIN, MOUSE; TLR4 PROTEIN, HUMAN; TLR4 PROTEIN, MOUSE; VESICULAR TRANSPORT ADAPTOR PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CAROTID ARTERY; CAROTID ARTERY INJURY; CELL DIFFERENTIATION; CELL MIGRATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; EMBRYO; GENE DELETION; HUMAN; HUMAN CELL; HYPERPLASIA; INTIMAL HYPERPLASIA; MACROPHAGE; MONOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; UBIQUITINATION; WILD TYPE; ANIMAL; BLOOD VESSEL INJURY; C57BL MOUSE; CELL CULTURE; CELL MOTION; CELL PROLIFERATION; DEFICIENCY; DISEASE MODEL; GENETICS; KNOCKOUT MOUSE; METABOLISM; NEOINTIMA; NEUTROPHIL CHEMOTAXIS; PATHOLOGY; PERITONEUM MACROPHAGE; TIME; VASCULITIS;

ADAPTOR PROTEINS, VESICULAR TRANSPORT; ANIMALS; CAROTID ARTERIES; CAROTID ARTERY INJURIES; CELL MOVEMENT; CELL PROLIFERATION; CELLS, CULTURED; CHEMOTAXIS, LEUKOCYTE; CYTOKINES; DISEASE MODELS, ANIMAL; HMGB1 PROTEIN; HUMANS; HYPERPLASIA; INFLAMMATION MEDIATORS; MACROPHAGES, PERITONEAL; MICE, INBRED C57BL; MICE, KNOCKOUT; MYELOID DIFFERENTIATION FACTOR 88; MYOCYTES, SMOOTH MUSCLE; NEOINTIMA; SIGNAL TRANSDUCTION; TIME FACTORS; TOLL-LIKE RECEPTOR 4; VASCULAR SYSTEM INJURIES; VASCULITIS;

EID: 84948087063     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.115.305789     Document Type: Article

References (45)

1. Fokkema M, den Hartog AG, Bots ML, van der Tweel I, Moll FL, de Borst GJ. Stenting versus surgery in patients with carotid stenosis after previous cervical radiation therapy: systematic review and meta-analysis. Stroke. 2012;43:793-801. doi: 10.1161/STROKEAHA.111.633743.
2. Andras A, Hansrani M, Stewart M, Stansby G. Intravascular brachytherapy for peripheral vascular disease. Cochrane Database Syst Rev. 2014;1:CD003504. doi: 10.1002/14651858.CD003504.pub2.
3. Seedial SM, Ghosh S, Saunders RS, Suwanabol PA, Shi X, Liu B, Kent KC. Local drug delivery to prevent restenosis. J Vasc Surg. 2013;57:1403-1414. doi: 10.1016/j.jvs.2012.12.069.
4. Rensing BJ, Hermans WR, Vos J, Beatt KJ, Bossuyt P, Rutsch W, Serruys PW. Angiographic risk factors of luminal narrowing after coronary balloon angioplasty using balloon measurements to reflect stretch and elastic recoil at the dilation site. The CARPORT Study Group. Am J Cardiol. 1992;69:584-591.
5. Dangas G, Kuepper F. Cardiology patient page. Restenosis: repeat narrowing of a coronary artery: prevention and treatment. Circulation. 2002;105:2586-2587.
6. Liu MW, Roubin GS, King SB III. Restenosis after coronary angioplasty. Potential biologic determinants and role of intimal hyperplasia. Circulation. 1989;79:1374-1387.
7. Welt FG, Rogers C. Inflammation and restenosis in the stent era. Arterioscler Thromb Vasc Biol. 2002;22:1769-1776.
8. Zheng Y, Gardner SE, Clarke MC. Cell death, damage-associated molecular patterns, and sterile inflammation in cardiovascular disease. Arterioscler Thromb Vasc Biol. 2011;31:2781-2786. doi: 10.1161/ATVBAHA.111.224907.
9. Tang D, Kang R, Zeh HJ 3rd, Lotze MT. High-mobility group box 1, oxidative stress, and disease. Antioxid Redox Signal. 2011;14:1315-1335. doi: 10.1089/ars.2010.3356.
10. Cai J, Wen J, Bauer E, Zhong H, Yuan H, Chen A. The role HMGB1 in cardiovascular biology: danger signals [published online ahead of print June 12, 2015]. Antioxid Redox Signal. doi: 10.1089/ars.2015.6408. http://online.liebertpub.com/doi/10.1089/ars.2015.6408.
11. Kalinina N, Agrotis A, Antropova Y, DiVitto G, Kanellakis P, Kostolias G, Ilyinskaya O, Tararak E, Bobik A. Increased expression of the DNAbinding cytokine HMGB1 in human atherosclerotic lesions: role of activated macrophages and cytokines. Arterioscler Thromb Vasc Biol. 2004;24:2320-2325. doi: 10.1161/01.ATV.0000145573.36113.8a.
12. Inoue K, Kawahara K, Biswas KK, Ando K, Mitsudo K, Nobuyoshi M, Maruyama I. HMGB1 expression by activated vascular smooth muscle cells in advanced human atherosclerosis plaques. Cardiovasc Pathol. 2007;16:136-143. doi: 10.1016/j.carpath.2006.11.006.
13. Karper JC, de Vries MR, van den Brand BT, Hoefer IE, Fischer JW, Jukema JW, Niessen HW, Quax PH. Toll-like receptor 4 is involved in human and mouse vein graft remodeling, and local gene silencing reduces vein graft disease in hypercholesterolemic APOE 3Leiden mice. Arterioscler Thromb Vasc Biol. 2011;31:1033-1040. doi: 10.1161/ATVBAHA.111.223271.
14. Andersson U, Tracey KJ. HMGB1 is a therapeutic target for sterile inflammation and infection. Annu Rev Immunol. 2011;29:139-162. doi: 10.1146/annurev-immunol-030409-101323.
15. Fiuza C, Bustin M, Talwar S, Tropea M, Gerstenberger E, Shelhamer JH, Suffredini AF. Inflammation-promoting activity of HMGB1 on human microvascular endothelial cells. Blood. 2003;101:2652-2660. doi: 10.1182/blood-2002-05-1300.
16. Porto A, Palumbo R, Pieroni M, Aprigliano G, Chiesa R, Sanvito F, Maseri A, Bianchi ME. Smooth muscle cells in human atherosclerotic plaques secrete and proliferate in response to high mobility group box 1 protein. FASEB J. 2006;20:2565-2566. doi: 10.1096/fj.06-5867fje.
17. Akira S, Takeda K, Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol. 2001;2:675-680. doi: 10.1038/90609.
18. Yang H, Antoine DJ, Andersson U, Tracey KJ. The many faces of HMGB1: molecular structure-functional activity in inflammation, apoptosis, and chemotaxis. J Leukoc Biol. 2013;93:865-873. doi: 10.1189/jlb.1212662.
19. Vink A, Schoneveld AH, van der Meer JJ, van Middelaar BJ, Sluijter JP, Smeets MB, Quax PH, Lim SK, Borst C, Pasterkamp G, de Kleijn DP. In vivo evidence for a role of toll-like receptor 4 in the development of intimal lesions. Circulation. 2002;106:1985-1990.
20. Hollestelle SC, De Vries MR, Van Keulen JK, Schoneveld AH, Vink A, Strijder CF, Van Middelaar BJ, Pasterkamp G, Quax PH, De Kleijn DP. Toll-like receptor 4 is involved in outward arterial remodeling. Circulation. 2004;109:393-398. doi: 10.1161/01.CIR.0000109140.51366.72.
21. Boekholdt SM, Agema WR, Peters RJ, Zwinderman AH, van der Wall EE, Reitsma PH, Kastelein JJ, Jukema JW; REgression GRowth Evaluation Statin Study Group. Variants of toll-like receptor 4 modify the efficacy of statin therapy and the risk of cardiovascular events. Circulation. 2003;107:2416-2421. doi: 10.1161/01.CIR.0000068311.40161.28.
22. Venereau E, Schiraldi M, Uguccioni M, Bianchi ME. HMGB1 and leukocyte migration during trauma and sterile inflammation. Mol Immunol. 2013;55:76-82. doi: 10.1016/j.molimm.2012.10.037.
23. Kim S, Kim SY, Pribis JP, Lotze M, Mollen KP, Shapiro R, Loughran P, Scott MJ, Billiar TR. Signaling of high mobility group box 1 (HMGB1) through toll-like receptor 4 in macrophages requires CD14. Mol Med. 2013;19:88-98. doi: 10.2119/molmed.2012.00306.
24. Venereau E, Casalgrandi M, Schiraldi M, et al. Mutually exclusive redox forms of HMGB1 promote cell recruitment or proinflammatory cytokine release. J Exp Med. 2012;209:1519-1528. doi: 10.1084/jem.20120189.
25. Yang H, Lundbäck P, Ottosson L, Erlandsson-Harris H, Venereau E, Bianchi ME, Al-Abed Y, Andersson U, Tracey KJ, Antoine DJ. Redox modification of cysteine residues regulates the cytokine activity of high mobility group box-1 (HMGB1). Mol Med. 2012;18:250-259. doi: 10.2119/molmed.2011.00389.
26. Calogero S, Grassi F, Aguzzi A, Voigtländer T, Ferrier P, Ferrari S, Bianchi ME. The lack of chromosomal protein Hmg1 does not disrupt cell growth but causes lethal hypoglycaemia in newborn mice. Nat Genet. 1999;22:276-280. doi: 10.1038/10338.
27. Yanai H, Ban T, Wang Z, et al. HMGB proteins function as universal sentinels for nucleic-acid-mediated innate immune responses. Nature. 2009;462:99-103. doi: 10.1038/nature08512.
28. Tang D, Billiar TR, Lotze MT. A Janus tale of two active high mobility group box 1 (HMGB1) redox states. Mol Med. 2012;18:1360-1362. doi: 10.2119/molmed.2012.00314.
29. Schober A. Chemokines in vascular dysfunction and remodeling. Arterioscler Thromb Vasc Biol. 2008;28:1950-1959. doi: 10.1161/ATVBAHA.107.161224.
30. Yang H, Wang H, Ju Z, et al. MD-2 is required for disulfide HMGB1-dependent TLR4 signaling. J Exp Med. 2015;212:5-14. doi: 10.1084/jem.20141318.
31. Hui DY. Intimal hyperplasia in murine models. Curr Drug Targets. 2008;9:251-260.
32. Nace GW, Huang H, Klune JR, Eid RE, Rosborough BR, Korff S, Li S, Shapiro RA, Stolz DB, Sodhi CP, Hackam DJ, Geller DA, Billiar TR, Tsung A. Cellular-specific role of toll-like receptor 4 in hepatic ischemia-reperfusion injury in mice. Hepatology. 2013;58:374-387. doi: 10.1002/hep.26346.
33. Schepers A, Eefting D, Bonta PI, Grimbergen JM, de Vries MR, van Weel V, de Vries CJ, Egashira K, van Bockel JH, Quax PH. Anti-MCP-1 gene therapy inhibits vascular smooth muscle cells proliferation and attenuates vein graft thickening both in vitro and in vivo. Arterioscler Thromb Vasc Biol. 2006;26:2063-2069. doi: 10.1161/01. ATV.0000235694.69719.e2.
34. Kim WJ, Chereshnev I, Gazdoiu M, Fallon JT, Rollins BJ, Taubman MB. MCP-1 deficiency is associated with reduced intimal hyperplasia after arterial injury. Biochem Biophys Res Commun. 2003;310:936-942.
35. Ali ZA, Bursill CA, Douglas G, McNeill E, Papaspyridonos M, Tatham AL, Bendall JK, Akhtar AM, Alp NJ, Greaves DR, Channon KM. CCR2-mediated antiinflammatory effects of endothelial tetrahydrobiopterin inhibit vascular injury-induced accelerated atherosclerosis. Circulation. 2008;118(suppl 14):S71-S77. doi: 10.1161/CIRCULATIONAHA.107.753558.
36. Heo SK, Yun HJ, Park WH, Park SD. Rhein inhibits TNF-alpha-induced human aortic smooth muscle cell proliferation via mitochondrial-dependent apoptosis. J Vasc Res. 2009;46:375-386. doi: 10.1159/000189798.
37. Savale L, Tu L, Rideau D, Izziki M, Maitre B, Adnot S, Eddahibi S. Impact of interleukin-6 on hypoxia-induced pulmonary hypertension and lung inflammation in mice. Respir Res. 2009;10:6. doi: 10.1186/1465-9921-10-6.
38. Räber L, Wohlwend L, Wigger M, et al. Five-year clinical and angiographic outcomes of a randomized comparison of sirolimus-eluting and paclitaxel-eluting stents: results of the Sirolimus-Eluting Versus Paclitaxel-Eluting Stents for Coronary Revascularization LATE trial. Circulation. 2011;123:2819-28, 6 p following 2828. doi: 10.1161/CIRCULATIONAHA.110.004762.
39. Izuishi K, Tsung A, Jeyabalan G, Critchlow ND, Li J, Tracey KJ, Demarco RA, Lotze MT, Fink MP, Geller DA, Billiar TR. Cutting edge: high-mobility group box 1 preconditioning protects against liver ischemia-reperfusion injury. J Immunol. 2006;176:7154-7158.
40. Antoine DJ, Harris HE, Andersson U, Tracey KJ, Bianchi ME. A systematic nomenclature for the redox states of high mobility group box (HMGB) proteins. Mol Med. 2014;20:135-137. doi: 10.2119/molmed.2014.00022.
41. Karper JC, Ewing MM, Habets KL, de Vries MR, Peters EA, van Oeveren-Rietdijk AM, de Boer HC, Hamming JF, Kuiper J, Kandimalla ER, La Monica N, Jukema JW, Quax PH. Blocking toll-like receptors 7 and 9 reduces postinterventional remodeling via reduced macrophage activation, foam cell formation, and migration. Arterioscler Thromb Vasc Biol. 2012;32:e72-e80. doi: 10.1161/ATVBAHA.112.249391.
42. Degryse B, Bonaldi T, Scaffidi P, Müller S, Resnati M, Sanvito F, Arrigoni G, Bianchi ME. The high mobility group (HMG) boxes of the nuclear protein HMG1 induce chemotaxis and cytoskeleton reorganization in rat smooth muscle cells. J Cell Biol. 2001;152:1197-1206.
43. Pålsson-McDermott EM, O'Neill LA. Signal transduction by the lipopolysaccharide receptor, Toll-like receptor-4. Immunology. 2004;113:153-162. doi: 10.1111/j.1365-2567.2004.01976.x.
44. Saxena A, Rauch U, Berg KE, Andersson L, Hollender L, Carlsson AM, Gomez MF, Hultgårdh-Nilsson A, Nilsson J, Björkbacka H. The vascular repair process after injury of the carotid artery is regulated by IL-1RI and MyD88 signalling. Cardiovasc Res. 2011;91:350-357. doi: 10.1093/cvr/cvr075.
45. Monaco C, Gregan SM, Navin TJ, Foxwell BM, Davies AH, Feldmann M. Toll-like receptor-2 mediates inflammation and matrix degradation in human atherosclerosis. Circulation. 2009;120:2462-2469. doi: 10.1161/CIRCULATIONAHA.109.851881.